Halix B.V. Appoints Dr. Lutz Hilbrich As Chief Executive Officer (CEO) and Thanks Alex Huybens for Leadership

Sep 19, 2024•10 months ago

Position

Chief Executive Officer

Company

HALIX B.V

Lutz Hilbrich

LeidenBiotechnologyManufacturing

Description

HALIX BV is pleased to announce the appointment of Dr Lutz Hilbrich as its new Chief Executive Officer (CEO), effective immediately. Dr Hilbrich brings over 20 years of experience in the biotechnology and pharmaceutical sectors, with a proven track record in the field of biosimilars, cell & gene therapy, and vaccines.

Company Information

Company

HALIX B.V

Location

Leiden, South Holland, Netherlands

About

HALIX B.V. is a biopharmaceutical CDMO for biologics, enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies, most notably the large-scale commercial drug substance manufacture of AstraZeneca's COVID-19 vaccine. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000 L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX is part of the family-owned Droege Group.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Daan hidden

hidden

Lutz hidden